 Kalie Tommerdahl
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 13 | 2026 | 322 | 3.710 |
Why?
| | Diabetes Mellitus, Type 2 | 13 | 2026 | 2602 | 2.250 |
Why?
| | Diabetes Mellitus, Type 1 | 20 | 2026 | 3937 | 2.040 |
Why?
| | Insulin Resistance | 7 | 2026 | 1244 | 1.290 |
Why?
| | Metformin | 2 | 2023 | 329 | 1.090 |
Why?
| | Hypoglycemic Agents | 7 | 2026 | 1399 | 0.900 |
Why?
| | Albuminuria | 2 | 2024 | 189 | 0.900 |
Why?
| | Kidney | 9 | 2026 | 1498 | 0.750 |
Why?
| | Glucosides | 4 | 2026 | 56 | 0.680 |
Why?
| | Benzhydryl Compounds | 4 | 2026 | 81 | 0.660 |
Why?
| | Prediabetic State | 2 | 2024 | 250 | 0.650 |
Why?
| | Cystic Fibrosis | 2 | 2020 | 1163 | 0.610 |
Why?
| | Fructosamine | 1 | 2019 | 11 | 0.610 |
Why?
| | Deoxyglucose | 1 | 2019 | 51 | 0.590 |
Why?
| | Glucose Tolerance Test | 1 | 2020 | 361 | 0.580 |
Why?
| | Serum Albumin | 1 | 2019 | 147 | 0.570 |
Why?
| | Glomerular Filtration Rate | 6 | 2025 | 765 | 0.550 |
Why?
| | Adolescent | 20 | 2026 | 22569 | 0.510 |
Why?
| | Insulin | 6 | 2026 | 2516 | 0.380 |
Why?
| | Cardiovascular Diseases | 4 | 2026 | 2190 | 0.360 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1101 | 0.350 |
Why?
| | Humans | 36 | 2026 | 145750 | 0.330 |
Why?
| | Child | 11 | 2026 | 22738 | 0.260 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2026 | 29 | 0.240 |
Why?
| | Biomarkers | 4 | 2026 | 4302 | 0.240 |
Why?
| | Cardio-Renal Syndrome | 1 | 2026 | 20 | 0.240 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.230 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.230 |
Why?
| | Young Adult | 11 | 2026 | 14250 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 138 | 0.220 |
Why?
| | Creatinine | 3 | 2022 | 515 | 0.220 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 47 | 0.200 |
Why?
| | Insulin Infusion Systems | 2 | 2026 | 480 | 0.200 |
Why?
| | Body Composition | 2 | 2025 | 693 | 0.200 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 148 | 0.190 |
Why?
| | Diabetic Ketoacidosis | 2 | 2025 | 210 | 0.190 |
Why?
| | Mitochondria, Muscle | 1 | 2024 | 120 | 0.190 |
Why?
| | Hyperoxia | 1 | 2024 | 107 | 0.180 |
Why?
| | Receptors, Prolactin | 2 | 2012 | 6 | 0.180 |
Why?
| | Male | 17 | 2026 | 72992 | 0.180 |
Why?
| | Bariatric Surgery | 1 | 2026 | 253 | 0.180 |
Why?
| | Patient Participation | 1 | 2025 | 440 | 0.180 |
Why?
| | Sex Characteristics | 2 | 2025 | 789 | 0.180 |
Why?
| | Glycoproteins | 1 | 2024 | 354 | 0.180 |
Why?
| | Female | 18 | 2026 | 79025 | 0.180 |
Why?
| | Adiposity | 2 | 2024 | 532 | 0.170 |
Why?
| | Obesity | 3 | 2025 | 3118 | 0.170 |
Why?
| | Bone Density | 1 | 2025 | 487 | 0.170 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1062 | 0.160 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 88 | 0.160 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 149 | 0.160 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 235 | 0.160 |
Why?
| | Transcriptional Activation | 2 | 2012 | 372 | 0.150 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 100 | 0.150 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 267 | 0.150 |
Why?
| | Oxygen | 2 | 2024 | 981 | 0.140 |
Why?
| | Risk Factors | 3 | 2026 | 10916 | 0.140 |
Why?
| | Glycation End Products, Advanced | 1 | 2019 | 81 | 0.140 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 544 | 0.140 |
Why?
| | Diabetic Retinopathy | 1 | 2021 | 209 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 668 | 0.130 |
Why?
| | Phenotype | 2 | 2022 | 3170 | 0.110 |
Why?
| | Cognition | 1 | 2024 | 1271 | 0.110 |
Why?
| | Inflammation | 1 | 2026 | 2883 | 0.110 |
Why?
| | Blood Glucose | 4 | 2026 | 2344 | 0.110 |
Why?
| | Hemodynamics | 3 | 2024 | 1118 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.090 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 18 | 0.090 |
Why?
| | Brain | 1 | 2025 | 2969 | 0.090 |
Why?
| | Signal Transduction | 1 | 2026 | 5223 | 0.090 |
Why?
| | HMGN2 Protein | 1 | 2011 | 3 | 0.090 |
Why?
| | STAT5 Transcription Factor | 1 | 2011 | 50 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 151 | 0.080 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 244 | 0.080 |
Why?
| | Mass Screening | 1 | 2019 | 1361 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 322 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5921 | 0.070 |
Why?
| | Cell Nucleus | 1 | 2011 | 588 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2025 | 3634 | 0.060 |
Why?
| | Adult | 6 | 2025 | 40867 | 0.060 |
Why?
| | Podocytes | 1 | 2026 | 80 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1454 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.050 |
Why?
| | Gray Matter | 1 | 2025 | 92 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 277 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 92 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 557 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 112 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1044 | 0.050 |
Why?
| | Threonine | 1 | 2022 | 44 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 340 | 0.050 |
Why?
| | Histidine | 1 | 2022 | 66 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 112 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2022 | 80 | 0.040 |
Why?
| | Leucine | 1 | 2022 | 116 | 0.040 |
Why?
| | Lipoproteins | 1 | 2022 | 166 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 627 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 119 | 0.040 |
Why?
| | Prognosis | 2 | 2025 | 4329 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1068 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 182 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2022 | 234 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Triglycerides | 1 | 2022 | 520 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2064 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2026 | 877 | 0.040 |
Why?
| | Glucose Clamp Technique | 1 | 2020 | 199 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2012 | 337 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2393 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1137 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2110 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2020 | 225 | 0.030 |
Why?
| | Pilot Projects | 1 | 2024 | 1897 | 0.030 |
Why?
| | Amino Acids | 1 | 2022 | 519 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 468 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2024 | 935 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 701 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 461 | 0.030 |
Why?
| | Body Mass Index | 1 | 2025 | 2447 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2012 | 1450 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 653 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5428 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1791 | 0.030 |
Why?
| | Genes, Neoplasm | 1 | 2012 | 26 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 49 | 0.020 |
Why?
| | Prolactin | 1 | 2012 | 87 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3915 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2203 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 887 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2011 | 334 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 618 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 442 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 848 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 442 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 855 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1708 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2131 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2883 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1247 | 0.020 |
Why?
| | United States | 1 | 2024 | 16122 | 0.010 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1329 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2240 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2865 | 0.010 |
Why?
| | Models, Biological | 1 | 2011 | 1764 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3551 | 0.010 |
Why?
| | Middle Aged | 1 | 2024 | 36297 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 4090 | 0.010 |
Why?
| | Animals | 1 | 2020 | 38100 | 0.010 |
Why?
|
|
Tommerdahl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|